The effect of defining chronic obstructive pulmonary disease by the lower limit of normal of FEV 1 /FVC Ratio in tiotropium safety and performance in respimat participants

Peter M.A. Calverley, Achim Mueller, Andrew Fowler, Norbert Metzdorf, Robert A. Wise

Research output: Contribution to journalArticlepeer-review

Abstract

Rationale: There is continuing debate about whether to define airflow obstruction by a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) below 0.70, or by ratio values falling below the age-dependent lower limit of normal (LLN) derived from general population data. Objectives: To determine whether using the LLN criterion affects the classification and outcomes of patients previously defined as having chronic obstructive pulmonary disease by the fixed FEV 1 /FVC ratio. Methods: We applied the LLN definition to pooled data from the Tiotropium Safety and Performance in Respimat study that used the fixed FEV 1 /FVC ratio for the clinical diagnosis of chronic obstructive pulmonary disease. Results: A total of 17,072 patients were analyzed; of these, 1,807 (10.6%) patients had a ratio greater than or equal to LLN. Patients with a ratio greater than or equal to LLN had similar risks of death from any cause and fatal major adverse cardiovascular (CV) event as those below LLN. Patients with a ratio below LLN had a significantly lower risk of major adverse CV events (hazard ratio = 0.69; 95% confidence interval [CI] = 0.55-0.86; P = 0.001), and had significantly greater risks of moderate to severe exacerbation (rate ratio = 1.48; 95% CI = 1.36-1.61; P < 0.0001) and severe exacerbation (rate ratio = 2.01; 95% CI = 1.68-2.40; P < 0.0001) when compared with patients greater than or equal to LLN. Study outcomes by treatment arm (5 μg tiotropium Respimat vs. 18 μgHandiHaler) were comparable. Conclusions: Using the LLN to define airflow obstruction would have excluded patients in the Tiotropium Safety and Performance in Respimat study with a higher risk of nonfatal major adverse CV events and a lower risk of exacerbation; study outcomes by treatment arm (2.5 μg/5 μg tiotropium Respimat vs. 18 μg HandiHaler) remained similar.

Original languageEnglish (US)
Pages (from-to)200-208
Number of pages9
JournalAnnals of the American Thoracic Society
Volume15
Issue number2
DOIs
StatePublished - Feb 2018

Keywords

  • Airflow obstruction
  • Disease exacerbation
  • Mortality
  • Tiotropium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'The effect of defining chronic obstructive pulmonary disease by the lower limit of normal of FEV <sub>1</sub> /FVC Ratio in tiotropium safety and performance in respimat participants'. Together they form a unique fingerprint.

Cite this